Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia

The purpose of the study is to assess the safety and efficacy of fluvastatin in children diagnosed with heterozygous familial hypercholesterolemia

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heterozygous Familial Hypercholesterolemia Mixed Dyslipidemia

Age range

10 year–16 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Novartis

Basel, Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

10-16 years old Heterozygous familial hypercholesterolemia

Exclusion criteria

Homozygous familial hypercholesterolemia Pregnant or lactating females Major surgery during the six month prior study

Other protocol defined inclusion and exclusion criteria may apply

Treatment and study plan

Fluvastatin

Drug

Sponsors and collaborators

Lead sponsor

Novartis

Industry

Registry information

Important dates

Study start: 2001
Primary completion: 2005
Study completion: 2005
First posted: Sep 15, 2005
Registry last updated: Nov 8, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed